Reports preclinical development of a humanized anti-DKK-1 antibody that aims to both stimulate bone formation and suppress bone resorption via Wnt/β-catenin and OPG-RANKL pathways.
Key Takeaways
- Murine antibody was humanized by CDR grafting with structure-guided back-mutations
- Antibody exhibited high-affinity binding and potent functional activity
- Our results demonstrate that the humanized antibody neutralizes DKK-1